Phase I/II trial of INO 4800 in China
Latest Information Update: 13 Aug 2020
At a glance
- Drugs INO 4800 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 10 Aug 2020 According to an Inovio Pharmaceuticals media release, regulatory authorities in China approved the clinical testing of INO-4800 by Advaccine in China, in July.
- 03 Mar 2020 According to Inovio Pharmaceuticals, Inc. media release, the company plans to publish/present results in Fall 2020.
- 03 Mar 2020 According to Inovio Pharmaceuticals, Inc. media release,the company plans to initiate this trial in April 2020.
Most Recent Events
Trial Overview
Purpose
This phase 1 trial will evaluate INO 4800 in China.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations Beijing Advaccine Biotechnology; Inovio Pharmaceuticals
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I/II
- Location China
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| INO 4800Primary Drug | Parenteral |
-
|
INO 4800
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 10 Aug 2020 | Other trial event | According to an Inovio Pharmaceuticals media release, regulatory authorities in China approved the clinical testing of INO-4800 by Advaccine in China, in July. Updated 13 Aug 2020 |
| 03 Mar 2020 | Other trial event | According to Inovio Pharmaceuticals, Inc. media release, the company plans to publish/present results in Fall 2020. Updated 09 Mar 2020 |
| 03 Mar 2020 | Other trial event | According to Inovio Pharmaceuticals, Inc. media release,the company plans to initiate this trial in April 2020. Updated 09 Mar 2020 |
| 04 Feb 2020 | New trial record | New trial record Updated 04 Feb 2020 |
| 30 Jan 2020 | Other trial event | According to an Inovio Pharmaceuticals media release, it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development of INO-4800 in China. Updated 05 Feb 2020 |
References
-
Inovio Pharmaceuticals. Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China. Media-Rel 2020;.
Media Release -
Inovio Pharmaceuticals. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. Media-Rel 2020;.
Media Release -
Inovio Pharmaceuticals. INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus. Media-Rel 2020;.
Media Release -
Inovio Pharmaceuticals. INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG